CClinicalTrials.gg
CompletedNCT03077932BetterOFFUpdated Aug 13, 2020

An App to Aid in Transitioning Off Opioid Medication

An interventional study of App Development and Open Pilot in Opiate Use Disorder and Opiate Withdrawal Syndrome, sponsored by Butler Hospital. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-08-13.

Sponsored by Butler Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Apr 2016, registered Mar 2017).
Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The investigators propose to develop a smartphone app (called BetterOFF) that will help patients manage opioid withdrawal during opioid medication taper and detoxification. The BetterOFF smartphone intervention will be a resource patients can access anytime and anywhere. If the BetterOFF intervention were to be effective in helping patients discontinue opioid medication, it could be integrated into the standard of care of office-based clinical practices, as well as substance use programs, thereby having a substantial public health impact.

Read the detailed description

Many of the growing number of patients prescribed long-term opioid medication (for a variety of reasons including a history of illicit opioid use or management of chronic pain) will express an interest in discontinuing medication. However, many patients, physically dependent on opioids, fear the withdrawal symptoms that inevitably occur with opioid medication discontinuation and will experience a decrease in their self-efficacy for abstinence at the end of a taper. As a result, tapering is often slow and done hesitantly, and relapse rates after an opioid taper are high and associated with broad consequences, including significant negative physical, mental, and social problems. Even with optimal tapering protocols, patients need novel approaches to manage the discontinuation of opiate agonist treatment. Given this important gap in opioid treatment delivery, we propose to develop a theoretically-driven, smartphone-delivered intervention (Better Off app) to help patients effectively manage the experience of opioid medication discontinuation.

02

Conditions studied

  • Opiate Use Disorder
  • Opiate Withdrawal Syndrome
03

In context

Substance Withdrawal Syndrome

128 studies on the registry are indexed under Substance Withdrawal Syndrome; 8 are open to participants now.

This study's enrollment of 15 is below the median of 53 across 93 interventional studies indexed under Substance Withdrawal Syndrome.

Browse Substance Withdrawal Syndrome studies →

Lead sponsor

Butler Hospital is the lead sponsor of 113 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • between 18-65 years of age;
  • currently receiving opioid medication;
  • interesting in discontinuing opioid medication
  • has a smartphone

Exclusion criteria

Exclusion Criteria:

  • non-English speaking.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Other
    App Development and Open Pilot

    Phase 1 (app development) will consist of: 1) development of the BetterOFF prototype; and 2) series of usability studies with patients interested in discontinuing opioid medication. Phase 2 (open pilot) will involve conducting a 12-week open pilot trial (n=20) to test the feasibility and acceptability of the BetterOFF app with patients tapering from opiate medication.

    Other: App Development and Open Pilot

Interventions

  • OtherApp Development and Open Pilot

    Phase 1 (app development) will consist of: 1) development of the BetterOFF prototype; and 2) series of usability studies with patients interested in discontinuing opioid medication. Phase 2 (open pilot) will involve conducting a 12-week open pilot trial (n=20) to test the feasibility and acceptability of the BetterOFF app with patients tapering from opiate medication.

06

What researchers measure

Primary outcomes

  1. Opiate use

    Days of opiate use at follow-up

    Time frame: 1 month post-taper

Secondary outcomes

  1. Fear of withdrawal symptoms

    Fear of withdrawal symptoms

    Time frame: 1 month post-taper

  2. Opiate Withdrawal

    opiate withdrawal symptoms

    Time frame: Baseline to 1 month post-taper

07

Study locations

1 site
  • Butler Hospital
    Providence, Rhode Island 02906, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 13, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03077932
Lead sponsor
Butler Hospital
Responsible party
Sponsor
First posted
Mar 13, 2017
Start date
Apr 1, 2016
Primary completion
Jun 30, 2020
Completion
Jun 30, 2020
Last update
Aug 13, 2020

Study contacts

Ana Abrantes, Ph.D.
principal investigator · Butler Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion